<DOC>
	<DOCNO>NCT00380211</DOCNO>
	<brief_summary>The purpose trial describe immunogenicity , safety , tolerability FluLaval™ TR Fluarix® , latter serve active comparator . The result compare standard immune response criterion , young elderly population .</brief_summary>
	<brief_title>Safety Immunogenicity FluLaval™ TR Fluarix® ( Influenza Vaccines ) Young Older Adults</brief_title>
	<detailed_description>This randomized trial ass immune protection offer Day 21 FluLaval™ TR , Fluarix® comparator . In group , immune response assess blood test 21 day follow vaccination . The safety tolerability study vaccine contrast comparator vaccine period 42 day follow vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female adult ( ≥18 yrs ) Stable health status Provide inform consent Access direct phone service ( NOT pay phone commonuse phone service ) Eligible female must negative pregnancy test Febrile illness ( &gt; 38.0°C oral temperature ) High blood pressure ( ≥140/90 mmHg ) Significant acute chronic Uncontrolled medical psychiatric illness within 1 month prior vaccination Immunosuppressive condition ( confirm suspect ) Renal impairment Hepatic dysfunction Complicated insulindependent diabetes mellitus Unstable cardiopulmonary disease Blood dyscrasia Cytotoxic , immunosuppressive drug , glucocorticoid use within 1 month vaccination ( nasal glucocorticoid allow ) History demyelinate disease Active neurological disorder Significant alcohol drug abuse Significant coagulation disorder ( prophylactic antiplatelet medication allow ) Influenza vaccine administrate within 6 month prior study vaccination Administration vaccine 30 day prior end study Use nonregistered drug within 30 day prior study vaccination Receipt immunoglobulins and/or blood product within 3 month study vaccination History suspect allergy previous influenza vaccine , constituent FluLaval™ TR Fluarix® , reaction egg consumption Pregnant nursing female subject Female subject protect acceptable contraception method ( except surgically sterile postmenopausal )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Thimerosal reduce content</keyword>
	<keyword>Immunogenicity , safety , reactogenicity</keyword>
	<keyword>Young elderly adult</keyword>
	<keyword>Influenza vaccine</keyword>
</DOC>